Welcome to our dedicated page for Leidos Holdings news (Ticker: LDOS), a resource for investors and traders seeking the latest updates and insights on Leidos Holdings stock.
Leidos Holdings, Inc. (NYSE: LDOS) is a leading science and technology company that provides services and solutions in defense, intelligence, civil, and health markets. Headquartered in Reston, Virginia, Leidos leverages the expertise of its 47,000 employees to tackle some of the world's most pressing challenges. The company is divided into several segments, each catering to specific industries:
- National Security and Digital: Focuses on cyber, logistics, security operations, and digital transformation for defense and intelligence customers.
- Health & Civil: Delivers public health solutions, care coordination, and environmental sciences services.
- Commercial & International: Covers security enterprise solutions, commercial energy offerings, and international business.
- Defense Systems: Develops advanced space, aerial, surface, and subsurface defense systems.
Leidos reported revenues of approximately $15.4 billion for the fiscal year ending December 29, 2023. The company’s recent projects include:
- Development of C2IMERA: An advanced command and control tool for the U.S. Air Force.
- MHS GENESIS Deployment: A federal electronic health record system implemented across all Department of Defense garrison facilities.
- Mayhem Hypersonic System: Advancing air-breathing hypersonic technologies through a collaborative national team effort.
Financially, Leidos had a strong 2023 with revenues up by 7%, achieving a record net income margin of 7.1% in the first quarter of 2024. The company remains committed to innovation, operational efficiency, and addressing emerging threats in national security and health.
Leidos Partnership for Defense Health has successfully deployed the MHS GENESIS electronic health record system to nine additional Military Treatment Facilities, including Walter Reed National Military Medical Center. This deployment impacts 14,000 clinicians and brings the operational count to over 2,700 locations, serving 6.6 million Department of Defense beneficiaries, or approximately 81% of garrison facilities. The deployment continues through 23 waves, aiming for full operational readiness across the continental U.S. and globally. Leidos reported revenues of approximately $14.4 billion for FY 2022, underscoring its leading role in defense health technology.
Leidos announced that 22 of its employees were recognized for excellence in STEM at the 2023 Black Engineer of the Year Awards held in February. The event attracted over 10,000 STEM professionals from diverse backgrounds. Among the honorees, Kendric Garmon received the STEM Professional Most Promising Engineer award, while Randall King and Jordan Thompson won the Science Spectrum Trailblazer award. Additionally, 18 employees were named BEYA Modern Day Technology Leaders, emphasizing the company's commitment to diversity and inclusion in STEM. Leidos takes pride in supporting its employees and fostering talent in these critical fields.
Leidos (NYSE: LDOS) has partnered with the University of Michigan for its $334 million Mayhem program, a hypersonic project awarded by the U.S. Air Force Research Laboratory. This partnership will provide U-M aerospace students with hands-on experience in Model-Based Systems Engineering (MBSE), contributing to the development of a virtual ecosystem for the Mayhem program. Students will gain significant industry experience while helping Leidos enhance efficiencies and drive innovation in aerospace technology. Leidos aims to develop a pipeline of talent through this initiative, creating future leaders in the field.
Leidos (NYSE: LDOS) will participate in the J.P. Morgan 2023 Industrials Conference on
RESTON, VA / ACCESSWIRE / March 1, 2023 / Leidos (NYSE:LDOS) announced the appointment of Thomas Bell as Chief Executive Officer, effective May 3, 2023. Bell, currently President of Defense at Rolls-Royce, will succeed Roger Krone, who has led the company since 2014 and will retire at the 2023 annual meeting. The board will also appoint Robert S. Shapard as independent chair post-meeting. Bell's selection followed a thorough process, and his extensive background in defense and aerospace is expected to provide continuity and leadership. Leidos reported approximately $14.4 billion in annual revenues for 2022.
Leidos (NYSE: LDOS) has secured a prime contract and three subcontracts from the Centers for Medicare and Medicaid Services (CMS) valued at approximately $102 million. The prime contract, which totals about $79 million, spans five years and will focus on IT operations and user services. Leidos aims to enhance CMS's mission-critical programs ensuring they remain agile and secure. Services include application migration, modernization, and support for hybrid cloud environments. This win aligns with Leidos’ strategy in IT modernization and could strengthen its market position.
Leidos (NYSE: LDOS) has announced the appointment of Thomas Bell as its new CEO, effective May 3, 2023. He will succeed Roger Krone, who will retire during the 2023 annual meeting of stockholders. Bell previously served as President at Rolls-Royce North America and has extensive experience in the aerospace sector, including roles at Boeing and Lockheed Martin. The company plans to appoint Robert S. Shapard as independent chair after the meeting. Leidos reported annual revenues of approximately $14.4 billion for the fiscal year ending December 30, 2022, emphasizing its strong position in defense, intelligence, civil, and health markets.
Leidos Holdings, Inc. (NYSE: LDOS) announced the expiration of its wholly-owned subsidiary's cash Tender Offer for any and all outstanding 2.950% Senior Notes due 2023. As of February 23, 2023, $391,572,000, or 78.31%, of the $500 million aggregate principal amount was validly tendered. Valid tendering holders will receive $995.77 for each $1,000 principal amount, plus accrued interest, on the Settlement Date, February 28, 2023. BofA Securities, Inc. and Citigroup Global Markets Inc. acted as dealer managers, while Global Bondholder Services Corporation served as the depositary agent. This offer is not a solicitation to sell any 2023 Notes.
Leidos Holdings, Inc. (NYSE: LDOS) announced the terms for a cash tender offer for its outstanding 2.950% Senior Notes due 2023. The offer is set to expire at 5:00 p.m. on February 23, 2023. Each $1,000 of the 2023 Notes validly tendered will receive cash consideration of $995.77, along with accrued interest since the last payment date of November 15, 2022. The Tender Offer is $500 million in size and is contingent on the successful completion of a new senior notes offering to cover repurchases. The company emphasized the need for note holders to review the Offer Documents carefully.
FAQ
What is the current stock price of Leidos Holdings (LDOS)?
What is the market cap of Leidos Holdings (LDOS)?
What does Leidos Holdings, Inc. do?
Where is Leidos Holdings, Inc. headquartered?
How many employees does Leidos have?
What are the main business segments of Leidos?
What were Leidos' revenues for the fiscal year 2023?
What is C2IMERA?
What is MHS GENESIS?
What recent project has Leidos completed for the Air Force Research Lab?
What are the recent financial highlights for Leidos?
How does Leidos contribute to national security?
